###### Summary box

What is already known about this subject?
=========================================

-   Long-term retention is key for ART effectiveness, both clinically and in terms of reducing HIV transmission.

-   Understanding the factors influencing long-term retention rates is crucial for designing effective ART programmes.

-   There are are numerous biomedical, social and behavioural determinants of attrition, but they have been often explored using retrospective data analysis.

What are the new findings?
==========================

-   In a prospective study, we confirmed gender-related differences in attrition.

-   Low CD4 levels (\<200 cells/µL) at enrolment were associated with an increased risk of attrition.

-   The level of attrition varies among health facilities.

-   Although decentralisation has positive effects on ART delivery, we observed that a high number of patients transferred out to other health facilities without official documentation attesting that they were still on ART.

What are the recommendations for policy and practice?
=====================================================

-   The observed gender difference suggests that separate ART programmes should be designed for women and for men.

-   The impact of low CD4 levels at enrolment on attrition suggests strategies should be strengthened to increase HIV counselling and testing, followed by quick ART initiation as per WHO guidelines.

-   Local policy makers should seek to understand the causes of the observed differences in attrition among health facilities.

Introduction {#s1}
============

The expansion of access to antiretroviral therapy (ART) over the last 10 years is a remarkable global health achievement, with over 17 million people living with HIV (PLWH) on ART in 2015, of whom nearly 10 million live in resource-limited settings.[@R1] According to the latest Joint United Nations Programme on HIV/AIDS (UNAIDS) data, the effects of scaling up ART were greatest in the world\'s most affected regions, eastern and southern Africa. Coverage increased from 24% (22% to 26%) in 2010 to 54% (50%−58%) in 2015 and the number of AIDS-related deaths has been reduced by 36% since 2010. In addition, adult HIV infections have decreased by 4%, with about 40,000 fewer new cases of adult HIV infection in 2015 than in 2010.[@R2]

Ethiopia, with an estimated 730,000 (600,000 to 970,000) PLWH and a HIV prevalence among adults of 1.2% (1.0% to1.5%) at the end of 2014, is one of the sub-Saharan countries which has implemented effective strategies to scale up ART. Since 2005, the Ethiopian government has introduced a programme making ART available on a free basis, with over 362,000 PLWH receiving ART in 2014. As a consequence, since the Millennium Declaration, the country has significantly reduced the incidence of HIV/AIDS as well as the number of deaths due to HIV/AIDS from 73,000 (60,000 to 93,000) in 2000 to 23,000 (17,000to 41,000) in 2014. However, despite the progress in scaling up ART, only 50% (41%66%) of HIV-infected people in Ethiopia currently receive ART.[@R3]

A further expansion of HIV treatment programmes is expected following the 2015 expansion in the WHO ART eligibility criteria, from a CD4 cell count of \<500 to all HIV patients irrespective of CD4, and introduction of the UNAIDS 90-90-90 strategy.[@R4]

However, to achieve the 90-90-90 treatment target, there is an urgent need to improve each step of HIV care in order to maximise the individual and public health benefits of ART. Suboptimal adherence and ART retention are a substantial barrier to programme effectiveness. According to recent reports, retention of the adult PLWH population may fall below 50% at 5 years after ART initiation in sub-Saharan Africa.[@R5]

Despite universal access to HIV care and treatment, long-term ART retention is a major health challenge in Ethiopia. Maintaining a high level of patient retention in care is key to obtaining personal and public health benefits. Determinants of attrition therefore need to be identified so appropriate interventions can be designed.

This prospective study aims to estimate retention in care and to identify predictors of attrition among patients initiating ART in seven public health facilities (HFs) located in Tigray in northern Ethiopia.

This paper is an extension of a previously published article describing the results of a 1-year follow-up analysis. Compared with the earlier report, this article provides more representative results since a longer follow-up period and a larger sample size have been used.[@R6]

Methods {#s2}
=======

Study design and setting {#s2a}
------------------------

We used data from the 'Cohort of African people Starting Antiretroviral therapy\' (CASA) project, a prospective, ongoing, multi-site study of a cohort of HIV-infected patients who started ART in seven urban and rural HFs located in Tigray, the northeastern region of Ethiopia. The HFs participating in the study include two health centres (Alamata Health Centre, Mekelle Health Centre), one university hospital (Ayder Referral Hospital), three general hospitals (Alamata General Hospital, Mekelle General Hospital and Lemlem Karl General Hospital of Michew) and one primary hospital (Mehoni Primary Hospital). The ART units in the health centres are run by two or three nurses, the primary hospital ART unit has three or four nurses and in some cases one health worker with a master\'s degree in infectious diseases, and the general hospital ART unit and the referral hospital ART unit have three or four nurses and one medical doctor.

Participants {#s2b}
------------

HIV-infected adults who fulfilled the WHO criteria for starting ART at the participating HFs were eligible for enrolment in our cohort. All individuals over 14 years of age who had initiated ART between 1 January 2013 and 31 December 2014 and who agreed to provide their home address and a telephone contact number were selected for this study. Follow-up data were available until December 2015.

Ethical considerations {#s2c}
----------------------

Ethics approval was obtained from the Health Research Ethics Review Committee of Mekelle University College of Health Science (reference number: ERC 0129/2012). All patients provided written informed consent. For patients aged 14--18, the informed consent form was signed by adult relatives acting as guardians (immediate families, e.g. father or mother or next of kin) and not by the patients themselves.

Outcome measures {#s2d}
----------------

The operational definitions of the outcomes used in this study are as follows:Loss to follow-up: patients who missed visits to the same HF for more than 3 months after the last scheduled visit.Stop ART medication: patients known to have stopped ART for any reason (personal or clinical decision).Mortality: patients recorded as dead on the patient\'s exit form.Transfer out: patients formally transferred to another HF. Transferred-out patients were not considered as retained in care because official documentation to certify that they were still on ART was not available. Transferred patients were considered as retained in the initial HF until the date they were transferred out.Retention in care: patients who were alive and receiving ART at the same HF after ART initiation (this does not include patients who were recorded as lost to follow-up (LTFU), who discontinued ART, who were deceased or who transferred out).Attrition from care: this is the opposite of retention and included patients who were LTFU, had discontinued ART, were recorded as deceased or had transferred out.

Independent variables {#s2e}
---------------------

The following demographic and clinical variables at enrolment were considered as potential predictors of attrition: gender, age, religion, educational status, WHO clinical stage (from stage I to stage IV), haemoglobin level, body mass index (BMI) calculated as weight (kg)/height (m)^2^ (underweight ≤18.5 , normal 18.6--25, overweight \>25), initial ART regimen, CD4 cell counts (within 6 months of starting HIV treatment) and the presence of active tuberculosis (TB) infection with *Mycobacterium tuberculosis* where the diagnosis had been made by sputum smear and chest x-ray.

Data source {#s2f}
-----------

The baseline visit and follow-up visits were carried out according to the national guidelines and the standard of care of the participating HFs. Data, including demographic and clinical information as well as the patient\'s current status (known to be dead, transferred-out, discontinued or LTFU) were systematically collected by ART nurses using forms specifically designed for this study (enrolment form, follow-up form, exit form).

Each HF used desktop software developed in the .Net framework (Microsoft) especially for this study to enter the demographic, clinical and laboratory data of participating patients. Data were first entered by a case manager (CM) from each site and then merged and managed in a central database. It was important for data completeness, reliability and validity to standardise the data collection procedures for all participating sites. Staff members responsible for collecting and entering study data received appropriate training and data monitoring was conducted throughout the study. The project implementation office in Ayder Hospital together with the project coordinating centre (Istituto Superiore di Sanità) in Italy were responsible for oversight of data quality and generating queries (missing data, inconsistencies in the data, potential errors) for each participating HF. The project implementation office staff were responsible for conducting regular site visits to assist local personnel with the queries and ensure procedures were followed appropriately.

Tracing of patients who failed to return for a scheduled visit {#s2g}
--------------------------------------------------------------

Routine HIV/AIDS care is provided in the participating HFs according to national guidelines. Support for PLWH is regularly provided by local community-based organisations and community health workers (CHWs). In the present study, the active participation of CHWs was enhanced to trace patients as described below. At each participating HF, patient data were entered by a study CM. At the beginning of each week (Monday), the CM prepared a list containing the details of patients who had missed their scheduled visit for more than 1 month. These lists were then given to trained CHWs who traced the patients using telephone interviews, face-to-face contacts or proxy information (family members or friends). Traced patients were asked why they had missed the scheduled visit. CHWs were trained to provide basic information on HIV and ART and on the importance of taking drugs regularly without interruption. Patients were asked to return to the HF and resume ART. At the end of each week (usually on Friday), CHWs returned the list to CMs together with the following information gathered during the week[@R1]: whether or not the patient had been traced,[@R2] how the patient had been traced (by phone, face to face, through other people),[@R3] the current vital status (alive or death) of the traced patient,[@R4] patient intent to return to the HF, and the reasons for his/her decision.

Statistical methods {#s2h}
-------------------

The primary outcome measure was retention in care 2 years after ART initiation. The Kaplan--Meier method was used to estimate the probability of retention in care, mortality, loss to follow-up, transfer out, and stopping ART medication at different time points. Univariate and multivariate Cox proportional hazards models with robust sandwich estimates, to account for within-HF correlation, were used to identify factors associated with attrition. All available demographic and clinical variables were considered as potential predictive factors and were included in the univariate analysis: type of HF, gender, age (14--25, 26--50, \>50 years), educational status (no education, primary, secondary, tertiary), religion (Orthodox Christian or other religion), BMI (≤18.5, 18.6--25, \>25), WHO clinical stage (I/II or III/IV), CD4 cell count (\<200 or ≥200 cells/µL), haemoglobin level (≤10 or \>10 g/dL), active TB, and initial treatment regimen (efavirenz-based or nevirapine-based). Predictor variables which had statistical significance in the univariate analysis (p\<0.2) were included in the multivariate analysis. An interaction term between CD4 cell count and haemoglobin level was also added in the multivariate model. Finally, variables with p\<0.05 (statistically significant) were identified as predictors of attrition in the final model. Follow-up of patients who stopped ART medication, were LTFU or had transferred out was censored at the date of the last visit to the HF. Time to death was censored at the date of recorded death. Follow-up of retained patients was censored at the end of the study period (31 December 2015). A sensitivity analysis to estimate each transferred patient\'s probability of being retained in care was also performed using a multiple imputation technique. Statistical analyses were performed using SPSS software, version 21.0 (SPSS, Chicago, IL) and the SAS statistical package, version 9.2 (SAS Institute, Cary, NC).

Results {#s3}
=======

Participant characteristics at ART initiation {#s3a}
---------------------------------------------

A total of 1198 patients were included in the analysis. A majority were women (63.4%) and their median age was 32 years. One thousand and sixty-eight (89.1%) patients were Orthodox Christians. Approximately half (44.5%) of the patients had no primary education. According to their BMI, 39.7% of patients were underweight. Slightly more than a half (51.5%) were clinically symptomatic (WHO III/IV). The median CD4 count at enrolment was 221 cells/µL. At ART initiation, about 9% of patients were co-infected with active TB. Most patients (89%) had haemoglobin values above 10 g/dL. The most common initial ART regimen was EFV-based (89.6%) ([table 1](#T1){ref-type="table"}).

###### 

Baseline characteristics

                                                   Total                 Ayder University Hospital   Mekelle General Hospital   Michew General Hospital   Alamata General Hospital   Mehoni Primary Hospital   Mekelle Health Centre   Alamata Health Centre
  ------------------------------------------------ --------------------- --------------------------- -------------------------- ------------------------- -------------------------- ------------------------- ----------------------- -----------------------
  Sex, n **(%)**                                                                                                                                                                                                                       
  Female                                           760 (63.4)            111 (58.1)                  72 (63.2)                  35 (46.7)                 62 (62.6)                  191 (64.3)                169 (70.7)              120 (65.6)
  Male                                             438 (36.6)            80 (41.9)                   42 (36.8)                  40 (53.3)                 37 (37.4)                  106 (35.7)                70 (29.3)               63 (34.4)
  Age (years) at start of ART, n (range), median   1198 (16--82), 32     191 (18--82), 33            114 (17--69), 36           75 (17--68), 37           99 (18--61), 33            297 (17--66), 30          239 (16--71), 32        183 (16--64), 32
  14--25, n (%)                                    191 (15.9)            29 (15.2)                   15 (13.2)                  4 (5.3)                   7 (7.1)                    71 (23.9)                 34 (14.2)               31 (16.9)
  26--50, n (%)                                    928 (77.5)            152 (79.6)                  92 (80.7)                  63 (84.0)                 84 (84.8)                  213 (71.7)                181 (75.7)              143 (78.1)
  \>50, n (%)                                      79 (6.6)              10 (5.2)                    7 (6.1)                    8 (10.7)                  8 (8.1)                    13 (4.4)                  24 (10.0)               9 (4.9)
  Religion, n (%)                                                                                                                                                                                                                      
  Orthodox Christian                               1068 (89.1)           183 (95.8)                  111 (97.4)                 69 (92.0)                 75 (75.8)                  243 (81.8)                231 (96.7)              156 (85.2)
  Muslim                                           126 (10.5)            8 (4.2)                     3 (2.6)                    6 (8.0)                   23 (23.2)                  53 (17.8)                 6 (2.5)                 27 (14.8)
  Protestant                                       4 (0.3)               --                          --                         --                        1 (1.0)                    1 (0.3)                   2 (0.8)                 --
  Educational status, n (%)                                                                                                                                                                                                            
  No education                                     533 (44.5)            36 (18.8)                   30 (26.3)                  25 (33.3)                 60 (60.6)                  219 (73.7)                46 (19.2)               117 (63.9)
  Primary                                          360 (30.1)            84 (44.0)                   33 (28.9)                  27 (36.0)                 23 (23.2)                  57 (19.2)                 84 (35.1)               52 (28.4)
  Secondary                                        200 (16.7)            50 (26.2)                   39 (34.2)                  14 (18.7)                 12 (12.1)                  15 (5.1)                  58 (24.3)               12 (6.6)
  Tertiary                                         105 (8.8)             21 (11.0)                   12 (10.5)                  9 (12.0)                  4 (4.0)                    6 (2.0)                   51 (21.3)               2 (1.1)
  BMI (kg/m^2^), n (%)                                                                                                                                                                                                                 
  ≤18.5                                            476 (39.7)            66 (34.6)                   54 (47.4)                  38 (50.7)                 54 (54.5)                  105 (35.4)                94 (39.3)               65 (35.5)
  18.6--25                                         652 (54.4)            107 (56.0)                  49 (43.0)                  29 (38.7)                 41 (41.4)                  184 (62.0)                132 (55.2)              110 (60.1)
  \>25                                             70 (5.8)              18 (9.4)                    11 (9.6)                   8 (10.7)                  4 (4.0)                    8 (2.7)                   13 (5.4)                8 (4.4)
  Clinical stage, n (%)                                                                                                                                                                                                                
  WHO I--II                                        581 (48.5)            52 (27.2)                   42 (36.8)                  47 (62.7)                 65 (65.7)                  155 (52.2)                134 (56.1)              86 (47.0)
  WHO III--IV                                      617 (51.5)            139 (72.8)                  72 (63.2)                  28 (37.3)                 34 (34.3)                  142 (47.8)                105 (43.9)              97 (53.0)
  CD4+ count (cells/µL), n (range), median         1173 (2--1777), 221   188 (2--1048), 215          114 (3--1202), 214         75 (3--519), 189          99 (4--722), 248           291 (6--1439), 224        239 (6--841), 207       167 (18--1777), 228
  \<200, n (%)                                     515 (43.0)            86 (45.0)                   53 (46.5)                  40 (53.3)                 39 (39.4)                  119 (40.1)                111 (46.4)              67 (36.6)
  ≥200, n (%)                                      658 (54.9)            102 (53.4)                  61 (53.5)                  35 (46.7)                 60 (60.6)                  172 (57.9)                128 (53.6)              100 (54.6)
  Missing data                                     25 (2.1)              3 (1.6)                     --                         --                        --                         6 (2.0)                   --                      16 (8.7)
  Haemoglobin (g/dL), n (%)                                                                                                                                                                                                            
  ≤10                                              112 (9.3)             18 (9.4)                    8 (7.0)                    6 (8.0)                   7 (7.1)                    24 (8.1)                  35 (14.6)               14 (7.7)
  \>10                                             1075 (89.7)           170 (89.0)                  106 (93.0)                 69 (92.0)                 91 (91.9)                  273 (91.9)                203 (84.9)              163 (89.1)
  Missing data                                     11 (0.9)              3 (1.6)                     --                         --                        1 (1.0)                    --                        1 (0.4)                 6 (3.3)
  Active TB, n (%)                                                                                                                                                                                                                     
  Yes                                              104 (8.7)             10 (5.2)                    10 (8.8)                   17 (22.7)                 7 (7.1)                    23 (7.7)                  26 (10.9)               11 (6.0)
  No                                               1094 (91.3)           181 (94.8)                  104 (91.2)                 58 (77.3)                 92 (92.9)                  274 (92.3)                213 (89.1)              172 (94.0)
  Initial treatment regimen, n (%)                                                                                                                                                                                                     
  Efavirenz-based                                  1073 (89.6)           185 (96.9)                  113 (99.1)                 75 (100.0)                99 (100.0)                 236 (79.5)                188 (78.7)              177 (96.7)
  Nevirapine-based                                 125 (10.4)            6 (3.1)                     1 (0.9)                    --                        --                         61 (20.5)                 51 (21.3)               6 (3.3)

Outcome measures after ART initiation {#s3b}
-------------------------------------

Kaplan--Meier estimates of retention in care were 89.3%, 83.9%, 82.1% and 79.8% at 6, 12, 18 and 24 months of follow-up, respectively ([figure 1](#F1){ref-type="fig"}). Attrition was mainly due to loss to follow-up, transferred-out patients and documented mortality. The loss to follow-up estimates were 3.2% at 6 months, 4.8% at 12 months, 5.8% at 18 months and 6.8% at 24 months. Transferred-out estimates were 4.6% at 6 months, 7.3% at 12 months, 8.2% at 18 months and 9.5% at 24 months. Mortality was 2.6% at 6 months, 4.0% at 12 months, 4.0% at 18 months and 4.4% at 24 months. Finally, the percentage of patients stopping ART was 0.6% after 6 months and 1.0% up to 24 months. The majority of events (deaths, loss to follow up, transferring out, ART discontinuations) occurred at 6 and 12 months of follow-up ([table 2](#T2){ref-type="table"}). A sensitivity analysis showed Kaplan--Meier estimates of retention of 91.7%, 87.3%, 86.0% and 84.3% at 6, 12, 18 and 24 months of follow-up, respectively (data not shown).
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###### 

Kaplan-Meier estimates of mortality, loss to follow-up, transfer out, stopping ART medication and attrition from care after ART initiation

  ---------------------------------------------------------------------------------------------------------------------------------------------------------
  Months of follow-up   Cumulative\   Mortality, n;\         Loss to follow-up,\    Transfer-out, n;\        Stopping ART,\          Attrition,\
                        events, n     % (95% CI)             n; % (95% CI)          % (95% CI)               n; % (95% CI)           % (95% CI)
  --------------------- ------------- ---------------------- ---------------------- ------------------------ ----------------------- ----------------------
   6 months             128           30; 2.6 (1.6 to 3.6)   37; 3.2 (2.2 to 4.2)   54; 4.6 (3.4 to 5.8)     7.0; 0.6 (0.2 to 1.0)   10.7 (8.9 to 12.5)

   12 months            193           45; 4.0 (2.8 to 5.2)   54; 4.8 (3.6 to 6.0)   83; 7.3 (5.7 to 8.9)     11; 1.0 (0.4 to 1.6)    16.0 (13.8 to 18.2).

   18 months            213           45; 4.0 (2.8 to 5.2)   64; 5.8 (4.4 to 7.2)   93; 8.2 (6.6 to 9.8)     11; 1.0 (0.4 to 1.6)    17.9 (15.7 to 20.1)

   24 months            231           48; 4.4 (3.2 to 5.6)   70; 6.8 (5.2 to 8.4)   102; 9.5 (7.7 to 11.3)   11; 1.0 (0.4 to 1.6)    20.2 (17.8 to 22.6)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------

Predictors of attrition from care {#s3c}
---------------------------------

The multivariate Cox proportional hazard model showed that male sex (HR 1.34, 95% CI: 1.04 to 1.74), CD4 count \<200 cells/µL (HR 1.48, 95% CI: 1.10 to 1.99) and the type of HF (Alamata Health Centre vs. Ayder Hospital: HR=2.02, 95% CI: 1.80 to 2.27; Alamata Hospital vs. Ayder Hospital: HR=2.81, 95% CI: 2.48 to 3.19; Mekelle Health Centre vs. Ayder Hospital: HR=2.09, 95% CI: 1.82 to 2.39; Mehoni Hospital vs. Ayder Hospital: HR=2.06, 95% CI: 1.86 to 2.28; Mekelle Hospital vs. Ayder Hospital: HR=2.15, 95% CI: 2.00 to 2.32; Michew Hospital vs. Ayder Hospital: HR=2.00, 95% CI: 1.68 to 2.39) were significantly associated with attrition ([table 3](#T3){ref-type="table"}).

###### 

Cox proportional hazards model of association between baseline characteristics and attrition from care

  ---------------------------------------------------------------------------------------------------
                                           Univariate analysis,\        Multivariate analysis,\
                                           HR\^ of attrition (95% CI)   HR\^ of attrition (95% CI)
  ---------------------------------------- ---------------------------- -----------------------------
  Health facility                                                       

   Ayder Hospital (university hospital)    Reference                    Reference

   Alamata Health Centre (health centre)   2.18 (1.28 to 3.71)\*        2.02 (1.80 to 2.27)\*\*

   Alamata Hospital (general hospital)     2.90 (1.62 to 5.19)          2.81 (2.48 to 3.19)

   Mekelle Health Centre (health centre)   2.08 (1.25 to 3.46)          2.09 (1.82 to 2.39)

   Mehoni Hospital (primary hospital)      1.95 (1.18 to 3.20)          2.06 (1.86 to 2.28)

   Mekelle Hospital (health centre)        2.18 (1.20 to 3.98)          2.15 (2.00 to 2.32)

   Michew Hospital (general hospital)      2.27 (1.17 to 4.41)          2.00 (1.68 to 2.39)

  Gender                                                                

   Female                                  Reference                    Reference

   Male                                    1.51 (1.16 to 1.95)\*        1.34 (1.04 to 1.74)\*\*

  Age (years)                                                           

   14--25                                  Reference                    --

   26--50                                  0.94 (0.66 to 1.33)          

   \>50                                    1.11 (0.63 to 1.96)          

  Educational status                                                    

   No education                            Reference                    --

   Primary                                 1.02 (0.75 to 1.38)          

   Secondary                               1.11 (0.77 to 1.59)          

   Tertiary                                0.99 (0.61 to 1.60)          

  Religion                                                              

   Orthodox Christian                      Reference                    --

   Other religions                         1.05 (0.69 to 1.59)          

  BMI (kg/m^2^)                                                         

   18.6--25                                Reference                    Reference

   ≤18.5                                   1.67 (1.28 to 2.17)\*        1.40 (0.99 to 1.98)

   \>25                                    0.69 (0.34 to 1.42)          0.79 (0.32 to 1.98)

  Clinical stage                                                        

   WHO I--II                               Reference                    Reference

   WHO III--IV                             1.30 (1.01 to 1.69)\*        1.10 (0.77 to 1.58)

  Active TB                                                             

   No                                      Reference                    Reference

   Yes                                     1.93 (1.33 to 2.80)\*        1.39 (0.92 to 2.10)

  Initial treatment regimen                                             

   Efavirenz-based                         Reference                    --

   Nevirapine-based                        1.17 (0.80 to 1.73)          

  CD4 count (cells/µL)                                                  

   ≥200                                    Reference                    Reference

   \<200                                   1.68 (1.29 to 2.19)\*        1.48 (1.10 to 1.99)^\*\*;^§

  Haemoglobin (g/dL)                                                    

   \>10                                    Reference                    Reference

   ≤10                                     1.40 (0.98 to 2.13)\*        1.40 (0.96 to 2.04)§
  ---------------------------------------------------------------------------------------------------

\*\*p Value \<0.05.

\^Hazard ratios estimated using robust sandwich estimators for variance to account for within-HF correlation.

\*p Value \<0.2.

§HR adjusted for interaction term between CD4 count and haemoglobin value

Discussion {#s4}
==========

This study shows that in these HFs in Tigray, there was a progressive loss of retention in care, which had declined to only 79.8% at 24 months after ART initiation. Loss to follow-up, documented mortality and transfer out to a different HF were the main causes of attrition. In addition, the study shows that the majority of loss to follow-up and deaths occurred in the first 12 months after ART initiation. These findings are in line with previous studies from Ethiopia[@R7] and other sub-Saharan African countries.[@R5]

However, our mortality estimate was lower than estimates reported in other studies conducted in Ethiopia[@R8] as well as in low- and middle-income countries.[@R13] Melaku *et al*, in a multi-clinic observational study conducted in Ethiopia, showed that the cumulative incidence of death was 6% at 6 months, 7% at 12 months and 8% at 24 months.[@R9] Another study, conducted in Ethiopia by Wubshet *et al*, showed that mortality was 3.7%, 5.6%, 7.1% and 8.1% at 6, 12, 18 and 24 months, respectively.[@R8] A systematic review in low- and middle-income countries by Gupta *et al* found that the overall estimate of mortality at 12 months after ART initiation was 14%, with the highest probability of 17% being found in sub-Saharan African countries, followed by Asia at 11%, and the Americas at 7%.[@R13] The mortality reported in this study could be an underestimate of true mortality as we were unable to accurately ascertain patient deaths. We expect that some of the patients classified as LTFU, transferred out or stopping ART, might have died.

This study is an update of a previously published article that reported preliminary results at 1 year following ART initiation and with fewer participating HFs.[@R6] In this study with a larger sample size, the retention in care estimate of 83.9% in the first 12 months of ART is in line with our previous findings showing a retention estimate of 85%. Data show that the majority of the loss to follow-up occurred in the first year of treatment. However, comparison of the results of this study (where local CHWs attempted to trace patients who failed to return for scheduled visits) with the results of our previous study (where a structured intervention to improve retention in care was not implemented) shows a slight decrease in loss to follow-up from 5.5% to 4.8% after 1 year since ART initiation. In addition, the data on retention rate at 24 months are encouraging and suggest that the Kaplan--Meier estimate of loss to follow-up during the second year is lower (over 60% of the loss to follow-up occurred during the first year of treatment). These observations suggest that efforts to improve retention in those at high risk of loss to follow-up should be mainly focused on the initial 12 months after starting ART. A longer follow-up is needed to confirm this hypothesis.

We identified the type of HF, male sex and CD4 count \<200 cells/µL as important determinants of attrition from care.

In our study, Ayder Referral Hospital showed a lower risk of attrition than the other HFs. We do not know the reason for this, but patients may have greater confidence in the health personnel at Ayder Referral Hospital as it is one of the most prestigious HFs in the country. Assefa *et al*, in a study conducted in 55 HFs in Ethiopia, found that retention in care varies across HFs with high, medium and low retention rates.[@R10] In another study carried out in south Ethiopia, Teshome *et al* reported a higher death rate and a lower LTFU rate in health centres than in hospitals.[@R14] However, a recent study in Ethiopia by Assefa *et al* found that the type of HF (health centre, secondary hospital or tertiary hospital) was associated with short-term but not long-term retention.[@R11] More specific studies to analyse the reasons for different retention rates among HFs are required.

Male gender is another factor independently associated with a higher rate of attrition from care. Differences in attrition from care between HIV-infected men and women have been observed in many other studies conducted in sub-Saharan Africa.[@R11] Some reports suggest that the reasons for lower retention among men may be due to gender differences in health-seeking behaviour, biological differences in response to ART, increased male risk for opportunistic infections and worse adherence of men to ART. Moreover, a study of eight South African ART programmes for HIV-infected adults starting ART suggested differences in mortality by gender may be due to background differences in mortality between men and women unrelated to the HIV/AIDS epidemic.[@R22] However, women are more also likely than men to access therapy. For example, because of prevention of mother to child transmission (PMTCT) programmes, it is probable that women present at HFs for ART earlier than men.[@R23]

Other studies conducted in Ethiopia have also shown that a low CD4+ cell count was an independent factor associated with a higher attrition rate.[@R7] This finding is also consistent with a large longitudinal ecological study conducted in nine African countries by Elus *et al*, which showed an association between a lower median CD4 count at ART initiation and higher 6-month attrition.[@R25] This finding suggests that innovative HIV testing strategies should be further supported to avoid CD4 levels falling too low. According to UNAIDS, more than 14.5 of the 36.7 million PLWH at the end of 2015 did not know their HIV status.[@R26]

This study has both strengths and limitations.

One limitation is the high proportion of patients who were transferred out to another HF. Although this is common in Ethiopia, as well as in other sub-Saharan countries, as a consequence of the scaling-up of decentralisation of ART delivery, in our study transferred-out patients were not considered as retained in care because official documentation to certify that they were still on ART was not always available. Therefore, the retention rate estimate might be an underestimate of the true value.

A further limitation should be considered. Although our study is being conducted according to routine clinical practice, the fact that patients were aware that they are part of a research study may have improved their level of retention.

Moreover, although CHWs are regularly involved in the participating HFs, additional CHW-based interventions for patient tracing and counselling, as implemented in the CASA project, can lead to increased retention as compared with standard practice. However, we were not able to estimate the impact on retention of the activities of the CHWs since there was no control group.

In addition, despite the 2-year follow-up, the observation period is still too short to properly evaluate the long-term retention rate, but the study is ongoing and is planned to last at least 5 years.

The strengths of this study are its multi-site and prospective design, the quality of data, and the intensive training of the study staff.

Based on our results, we believe that combination strategies to address the many factors affecting patient retention need to be implemented, while more research on innovative models of care is needed. The different levels of attrition from care observed in our study among different types and locations of HFs suggest that action to decrease inequalities in the quality of care among HFs should be a priority for policy makers. Observed attrition differences between genders suggest that new specific interventions designed for women and men should also be explored separately. Interventions aimed at networking clinical centres and developing systems for tracking patients who transfer out should be implemented. Finally, the active involvement of CHWs in specific activities may have improved retention in care in our study. Therefore, we believe that the active involvement of well-trained CHWs should be further encouraged.[@R27]
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